15 December 2017

Multi Centre Beta Testing Commences for Cloud-Based AI Prototype

Resonance Health (ASX: RHT) is pleased to announce the next major milestone in the development of its ground breaking artificial intelligence (AI) solution, with submissions now being received from hospital sites interested in participating in the multi-centre trial.

Twenty countries have been strategically selected throughout emerging growth markets (EGM) for this next stage of testing, with the Company looking to finalise applications from sites over the coming weeks.

This follows on from a successful first stage beta test. Subsequent user interface and user experience upgrades on the Company's liver-iron-concentration (LIC) AI solution are now being carried out.

Delivery of the AI solution for iron measurement will be provided by Resonance Health's newly developed in-house web portal platform, with the Company intending to utilise this platform to provide a diverse range of automated medical solutions in the future.

The AI test will provide emerging growth markets with iron overload assessment at a significantly lower price point to FerriScan®, allowing Resonance Health to handle higher volumes with greater efficiency.

This multi-centre beta-testing is considered the final stage of tests before regulatory approval and commercial release of the AI solution.

Further updates will continue to be provided as work progresses.

Martin Blake

Chairman RHT

For further information, please contact:

Alison Laws

Chief Business Development Officer, Resonance Health

E: alisonl@resonancehealth.com   P: +61 (0)8 9286 5300